Full text loading...
-
The State of the Problem of Achieving Extremely Low LDL Levels
- Source: Current Pharmaceutical Design, Volume 27, Issue 37, Oct 2021, p. 3841 - 3857
-
- 01 Oct 2021
- Previous Article
- Table of Contents
- Next Article
Abstract
Patients who have achieved very low low-density lipoprotein CH (LDL-C) levels in clinical trials have shown the lowest cardio-vascular risk. The current clinical guidelines set such a concentration for LDL-C as < 1.4 mmol/L. However, the question of minimum permissible target values of the lipids remains unresolved. A number of experimental and clinical studies showed some unfavorable consequences of low LDL-C levels At the same time, the modern arsenal of lipid lowering drugs allows reducing LDL-C levels to extremely low values. This review presents an analysis of literature about the safety of low lipid spectrum parameters.
© Bentham Science Publishers